MannKind touts good news from Afrezza inhaled insulin trial

After being dogged by regulatory setbacks and demands for new trials, MannKind ($MNKD) says it has gathered clearly positive late-stage data on its inhaled insulin Afrezza from a pair of Phase III studies on Type 1 and Type 2 diabetes. Report